Le study, as well as the results are unlikely to be confirmed in
Le study, and also the benefits are unlikely to become confirmed inside a potential manner. Even so, if these findings had been to become validated by way of a equivalent evaluation of data from 1 or additional of your independent randomized phase III trials, the clinical determination of malignant ascites could be a uncomplicated and cost-effective way of selecting sufferers with the greatest probability of long-term benefit from bevacizumab.Author Manuscript Author Manuscript Author Manuscript Author ManuscriptACKNOWLEDGEMENTSThis study was supported by National Cancer CD162/PSGL-1 Protein site Institute grants towards the Gynecologic Oncology Group Administrative Workplace (CA 27469), the Gynecologic Oncology Group Statistical and Information Center (CA 37517), the NRG Oncology SDMC grant U10 CA180822 plus the NRG Oncology Operations grant U10CA 180868. This investigation was also supported by the GOG Young Investigator Award. The clinical trial upon which this manuscript is primarily based was sponsored by the Cancer Therapy Evaluation Program (CTEP) with the National Cancer Institute (NCI), beneath the Collaborative Research and Development Agreement (CRADA) for bevacizumab in between NCI and Genentech, Inc. The following Gynecologic Oncology Group member institutions participated within this study: Roswell Park Cancer Institute, University of Alabama at Birmingham, Duke University Health-related Center, Abington Memorial Hospital, Walter Reed Army Health-related Center, Wayne State University, University of Minnesota Medical School, Mount Sinai College of Medicine, Northwestern Memorial Hospital, University of Mississippi Healthcare Center, ColoradoGynecol Oncol. Author manuscript; available in PMC 2016 October 01.Ferriss et al.Page eight Gynecologic Oncology Group P.C., University of California at Los Angeles, University of Washington, University of Pennsylvania Cancer Center, Milton S. Hershey Health-related Center, University of Cincinnati, University of North Carolina School of Medicine, University of Iowa Hospitals and Clinics, University of Texas Southwestern Healthcare Center at Dallas, Indiana University School of Medicine, Wake Forest University College of Medicine, University of California Health-related Center at Irvine, Rush-Presbyterian-St. Luke’s Health-related Center, Magee Women’s Hospital, SUNY Downstate Health-related Center, University of Kentucky, University of New Mexico, The Cleveland Clinic Foundation, State University of New York at Stony Brook, Washington University College of Medicine, Memorial Sloan-Kettering Cancer Center, Cooper Hospital/University Healthcare Center, Columbus Cancer Council, MD Anderson Cancer Center, University of Massachusetts Health-related College, Fox Chase Cancer Center, Women’s Cancer Center, University of Oklahoma, University of Virginia Health Sciences Center, University of Chicago, Mayo Clinic, Case Western Reserve University, Tampa Bay Cancer Consortium, Yale University, GOG Japan-Saitama Healthcare University International Healthcare Center, University of Wisconsin Hospital, Cancer Trials Help Unit, University of Texas – Galveston, Females and Infants Hospital, Korean Gynecologic Oncology Group, The Hospital of Central Connecticut, Georgia Core, GYN Oncology of West Michigan, PLLC, Aurora Women’s Pavilion of West Allis Memorial Hospital, and Neighborhood Clinical Oncology Plan.Author Manuscript Author Manuscript Author Manuscript Author Manuscript
MOLECULAR AND CLINICAL ONCOLOGY 7: 787-797,Evaluation of epidermal growth element receptor serum levels and their association with clinicopathological characteristics in patients with colorectal CCN2/CTGF Protein site cancerM.